MedTrace Logo

Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER

NCT01857947 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2014-12-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).

Conditions

  • Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation

Interventions

OTHER

AECOPD Mr proADM

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • ThermoFisher Scientific Brahms Biomarkers France

    lead INDUSTRY

Principal Investigators

  • Nicolas Roche, MD PHD · Hotel Dieu Hospital Paris

  • Martin Dres, MD · Hopital Bicêtre Le Krémlin Bicêtre

  • Pierre Hausfater, MD PHD · Pitié Salpétrière Hospital Paris

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01857947 on ClinicalTrials.gov